Among 418 blood culture isolates of viridans group streptococci obtained between 1995 and 1997, the in vitro rates of nonsusceptibility to penicillin, erythromycin, tetracycline, and trimethoprim-sulfamethoxazole were 28, 29, 24, and 14%, respectively. The most prevalent group (125 strains) was Streptococcus mitis, followed by Streptococcus sanguis (56 strains). For 236 (56%) strains resistant to one or more antibiotics, the ciprofloxacin MIC at which 90% of the isolates were inhibited (MIC 90 ) was 4 g/ml, whereas the MIC 90 s of trovafloxacin, grepafloxacin, and gatifloxacin were 0.25 g/ml.
Viridans group streptococci, although part of the normal human flora, are a common cause of sepsis in neutropenic patients (3) and bacterial endocarditis (17) . Recently, there have been several reports describing emerging antimicrobial resistance in this group of streptococci (1, 2, 7, 15) . In 1996, 56% of strains in the United States were nonsusceptible to penicillin (7) , an antimicrobial that had exhibited good activity against these organisms 20 years ago (4) .
This study examined the activities of several antimicrobial agents, comprising those commonly used for treating infections caused by viridans group streptococci and those that could be potentially useful, such as the fluoroquinolones, with enhanced activity against gram-positive organisms (14) .
Between May 1995 and March 1997, 418 blood culture isolates of viridans group streptococci were collected through the Canadian Bacterial Surveillance Network, a system of 55 private laboratories and community-and university-affiliated hospitals representing nine provinces across Canada, of which 39 provided 3 or more isolates. Isolates were sent to Mount Sinai Hospital for susceptibility testing and species identification. The latter was carried out with a combination of standard biochemical tests (18) , the Vitek GPI system (bioMerieux Vitek Inc., Hazelwood, Mo.), and the API 20 Strep system (bioMerieux sa, Marcy l'Etoile, France) according to the manufacturer's instructions. Susceptibility testing was performed by broth microdilution, in accordance with National Committee for Clinical Laboratory Standards (NCCLS) guidelines (13) . Panels were prepared in-house, by using cation-adjusted Mueller-Hinton broth (Difco Laboratories, Detroit, Mich.) supplemented with 5% lysed horse blood. The in vitro activities of the following agents were tested: penicillin, cefuroxime, ceftriaxone, cefotaxime, erythromycin, clindamycin, vancomycin, tetracycline, trimethoprim-sulfamethoxazole (TM/S [19: 1] ), ciprofloxacin (Sigma-Aldrich Canada, Oakville, Ontario), sparfloxacin (Rhone-Poulenc Rorer, Collegeville, Pa.), levofloxacin (Ortho-McNeil Pharmaceuticals, Spring House, Pa.), and gatifloxacin (Bristol-Myers Squibb Company, Princeton, N.J.). Streptococcus pneumoniae ATCC 49619 was used as a control. MICs of drugs were read after 20 to 24 h of incubation in ambient air at 35°C.
Relatively high rates of resistance against several antimicrobials were noted (Table 1) . Among the 418 isolates, 116 (28%) were nonsusceptible to penicillin, with MICs ranging from 0.12 to 32 g/ml (MIC at which 90% of the isolates are inhibited [MIC 90 ], 1 g/ml). Of these, 91 strains (22%) demonstrated intermediate resistance (MIC, 0.25 to 2 g/ml), and 25 (6%) showed high resistance (MIC, Ն4 g/ml). Among the strains showing high resistance, the penicillin MICs were 4 g/ml for 16 strains, 8 g/ml for 9 strains, and 32 g/ml for 1 strain. The rate of penicillin nonsusceptibility found in this study is lower than the rates of 56% reported in the United States (7) and 37% in New Zealand (15) . In a study in Spain of 410 viridans strains isolated from blood, 34% were found to be nonsusceptible to penicillin (5) . Predictably, nonsusceptibilities to both amoxicillin and ceftriaxone were also relatively high at 12%, and the MIC 90 s of these two agents were the same as that for penicillin at 1 g/ml.
Interestingly, although 29% of the strains were nonsusceptible to erythromycin, only 4% were nonsusceptible to clindamycin, and these did not show inducible resistance. This suggests that resistance was not due to the presence of an erm methylase, which confers resistance to macrolides, lincosamides, and streptogramin B type antimicrobials (22) , but is more likely due to the high prevalence of an efflux mechanism, such as is conferred by the mef gene, which selectively confers resistance to erythromycin but not to clindamycin (20) . High rates of resistance to erythromycin in blood culture isolates have been observed previously in Spain (39%) (1) and the United States (38%) (7); however, susceptibility to clindamycin was not examined. Other antibiotics to which strains showed a high level of nonsusceptibility were tetracycline at 24% and TM/S at 14%.
Emergence of high rates of resistance to various antimicrobials was surprising, considering that 173 (60%) strains were from community-based hospitals (Ͻ200 beds) rather than tertiary care hospitals. There was no significant difference (P ϭ 0.8) in levels of penicillin resistance between strains from the two groups of hospitals, and patterns of resistance to the other antibiotics were also similar.
In S. pneumoniae, it has been noted that penicillin-resistant strains tend to be resistant to other unrelated antimicrobials, and resistance is generally low in penicillin-susceptible strains (19) . However, this did not appear to be the case in this group of viridans streptococci, and rates of resistance to certain antibiotics were relatively high among penicillin-susceptible strains. Of 302 penicillin-susceptible isolates, 60 (20%) showed nonsusceptibility to erythromycin, 68 (23%) were nonsusceptible to tetracycline, and 15 (5%) were nonsusceptible to TM/S. In the case of tetracycline, the resistance rates were almost identical in penicillin-susceptible and nonsusceptible strains at 23 and 25%, respectively, which is different from the pattern found in S. pneumoniae strains.
Of the 418 strains tested, 236 showed resistance to one or more of the antimicrobial agents listed in Table 1 . These strains were tested against a panel of fluoroquinolones as shown in Table 2 . The ciprofloxacin MIC 50 and MIC 90 were 4 and 2 g/ml, respectively, and the ofloxacin MIC 90 and MIC 50 were both 2 g/ml. By comparison, with the exception of levofloxacin (with a MIC 90 of 1 g/ml), the MICs of the other fluoroquinolones were 0.5 or less. The MICs of trovafloxacin, grepafloxacin, and gatifloxacin were at least fourfold lower than those of ciprofloxacin, ofloxacin, and levofloxacin. Two strains showed reduced susceptibility to all of the fluoroquinolones tested, with MICs of ciprofloxacin and ofloxacin of 32 g/ml and MICs of sparfloxacin, gatifloxacin, and grepafloxacin of 4 to 8 g/ml.
Identification at the group level was carried out with the 236 strains showing resistance to one or more antibacterial agents. Antimicrobial activity against 211 strains belonging to the most prevalent groups is shown in Table 3 . Groups which encompassed fewer than 10 strains were not included: Streptococcus milleri (7 strains), Streptococcus bovis (6 strains), and Streptococcus mutans (3 strains). In addition, small numbers of strains (e.g., three or four) which did not fall into easily identifiable groups, such as Streptococcus acidominus, were also excluded. The largest number of isolates (59%) belonged to the Streptococcus mitis group. Of 125 S. mitis isolates, 50 (40%) were nonsusceptible to penicillin and 66 (53%) were nonsusceptible to erythromycin. The two strains which showed reduced susceptibility to all of the fluoroquinolones (Table 2) belonged to the S. mitis group. In the Streptococcus sanguis group, comprising 56 strains, 55% were nonsusceptible to penicillin.
The results of this study show that 28% of bloodstream isolates of viridans group streptococci are nonsusceptible to penicillin, with as many as 40% of S. mitis strains, the most prevalent group, showing nonsusceptibility. The MIC of penicillin for one S. milleri strain (Streptococcus intermedius) was 32 g/ml. This is of concern, since S. pneumoniae can acquire resistance, as represented by a MIC of penicillin as high as 64 g/ml, by horizontal transfer from S. mitis in vitro (8, 12) . The current rate of penicillin resistance (intermediate plus high) in pneumococci in Canada is 14% (6, 19) , which is considerably less than that found in this study for viridans group streptococci.
Our data indicate that the newer fluoroquinolones exhibit good in vitro activity against viridans group streptococci, including isolates known to have intermediate or high resistance to penicillin and other ␤-lactam antibiotics. Currently, there are no interpretative standards with respect to the efficacy of most fluoroquinolones against streptococci. However, trovafloxacin, grepafloxacin, and gatifloxacin showed excellent ac- tivity in vitro, with MIC 90 s of 0.25 g/ml, a 4-to 16-fold decrease compared to levofloxacin, ofloxacin, and ciprofloxacin. Trovafloxacin has been shown to decrease bacterial counts of an S. mitis strain and an S. sanguis strain showing reduced susceptibility to ciprofloxacin in an animal model of streptococcal endocarditis (9) . Our work confirms the results of other studies showing that newer fluoroquinolones have better activity against clinical isolates of viridans streptococci (9, 11) . However, mutations in the topoisomerase genes parC and gyrA have been shown to occur both in vitro and in vivo in response to fluoroquinolone exposure and treatment (21) . Blood culture isolates of viridans group streptococci with reduced susceptibility to ciprofloxacin (MIC 90 , 8 to 16 g/ml) have already been described (9) (10) (11) 16) , and resistance to newer fluoroquinolones will likely develop. Consequently, ongoing surveillance for the development of fluoroquinolone resistance in viridans streptococci is essential. 
